The US Food and Drug Administration cleared a suite of Eko’s cloud-based software apps that use artificial intelligence with a digital stethoscopes to assist physicians in detecting potential cardiac conditions such as heart murmurs and atrial fibrillation, the company announced on 28 January.
According to Eko, the algorithms cleared by the FDA are the first of their kind designed to be used on Eko's digital stethoscopes that were released in 2015 and now used in 4,000 clinics and hospitals around the US